BI 836880

Drug Profile

BI 836880

Alternative Names: Anti-VEGF/Ang2 Nanobody®; Bi-specific Anti-VEGF/Ang2 Nanobody®

Latest Information Update: 03 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ablynx
  • Developer Boehringer Ingelheim
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 Mar 2018 Boehringer Ingelheim plans a phase I trial of BI 836880 in combination with BI 754091 for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease), in April 2018 (NCT03468426)
  • 01 Apr 2016 Boehringer Ingelheim initiates a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in France (NCT02689505)
  • 26 Feb 2016 Boehringer Ingelheim plans a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in Spain and France (NCT02689505)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top